---
status: "🟢 Near-Final"
category: "grant"
type: "solution-summary"
due: "2026-04-08"
priority: "P0-Critical"
tags: [ARPA-H, Delphi, grant, solution-summary, quantum-biology]
created: "2026-03-22"
updated: "2026-03-24"
---
# ARPA-H DELPHI — 6-PAGE SOLUTION SUMMARY

> [!target] SUBMISSION TARGET: ARPA-H Delphi — April 8, 2026 | Status: NEAR-FINAL | Completion: ~95%

> PI: [Name] | Co-PI: Alessandra Lanzara (UCB Physics) | Collaborator: Markus Buehler (MIT DMSE)

---

## PAGE 1 — EXECUTIVE SUMMARY

### Problem

Current cancer diagnostics miss early-stage metabolic shifts; aging biomarkers lack mechanistic grounding. Both fields operate in silos despite sharing a common quantum-biological substrate. No existing platform unifies cancer and aging detection through a single mechanistic framework.

**In plain terms:** Every living cell runs on quantum mechanics — electrons tunnel through enzymes, energy flows coherently through molecular networks, and magnetic fields influence cellular signaling through spin physics. We have discovered that cancer hijacks these quantum processes (turning them up too high) while aging degrades them (letting them fall apart). By measuring the molecular fingerprints of these quantum systems in a drop of blood, we can detect both cancer and aging from a single test.

### Insight

Cancer **amplifies** and aging **decoheres** the same four quantum protection architectures:

1. **FMO excitonic coherence** — wavelike energy transfer in light-harvesting analogs
2. **Enzyme quantum tunneling** — hydrogen and electron tunneling in metabolic enzymes
3. **Mitochondrial ETC quantum transfer** — electron tunneling through respiratory chain complexes
4. **Cryptochrome spin coherence** — radical pair spin dynamics in flavoproteins

These architectures are not independent — they share metabolite substrates (NADH, FAD, ATP, GSH) that serve as measurable indicators of quantum protection status.

### Solution

**Probius QES** label-free vibrational spectroscopy captures NADH/FAD/ATP/GSH fingerprints from 2–4 µL plasma (finger-stick). These four metabolite signatures encode opposing cancer↑ / aging↓ trajectories that are integrated into a **Quantum Protection Index (QPI)** — a composite diagnostic score.

### Impact

A unified quantum-protection diagnostic platform enabling:
- **Earlier cancer detection** through metabolic quantum amplification signatures
- **Mechanistic aging quantification** through decoherence trajectory tracking
- **Single finger-stick sample** — point-of-care, population-scalable
- **Longitudinal monitoring** — track quantum protection status over time

### Team

| Member | Institution | Role |
|---|---|---|
| PI | UCB / UCSF | Quantum biology integration, QPI development |
| Alessandra Lanzara | UCB Physics | Ultrafast mid-IR/THz spectroscopy, ground-truth validation |
| Markus Buehler | MIT DMSE | ScienceClaw × Infinite swarm AI, computational modeling |
| Clinical Partners | UCSF | Clinical translation, cohort recruitment, regulatory |

---

## PAGE 2 — TECHNICAL APPROACH

### Architecture Overview

The quantum protection framework rests on four experimentally validated architectures:

| Architecture | Mechanism | Key Evidence | Cancer Signature | Aging Signature |
|---|---|---|---|---|
| 1. FMO Coherence | Excitonic energy transfer | Engel 2007 | Enhanced coherence | Shortened lifetime |
| 2. Enzyme Tunneling | H-transfer / e⁻ tunneling | Moser-Dutton | Accelerated tunneling | Impaired tunneling |
| 3. ETC Transfer | Mitochondrial e⁻ transport | Complex I studies | Warburg amplification | NAD+ depletion |
| 4. Spin Coherence | Radical pair dynamics | Hore-Mouritsen 2016 | ROS-altered spin states | Oxidative disruption |

### Quantum Protection Index (QPI) Model

$$QPI = w_1 \cdot f(NADH) + w_2 \cdot f(FAD) + w_3 \cdot f(ATP) + w_4 \cdot f(GSH)$$

- QPI > 0 → Cancer trajectory | QPI < 0 → Aging trajectory | QPI ≈ 0 → Homeostasis
- Full mathematical framework: [[01-Core-Thesis/Quantum-Protection-Index-QPI-Model]]

### Measurement Strategy

**Probius QES** operating principles:
- Label-free vibrational spectroscopy on 2–4 µL plasma
- Spectral targets: NADH (340/460 nm), FAD (450/525 nm), GSH (thiol vibrational modes), ATP (phosphate stretches)
- Sample-to-result: < 15 minutes from finger-stick

### Top 5 Candidate Biomarkers

Selected for maximum architecture coverage and Probius readout strength — see [[00-Flight-Deck/Top-5-Delphi-Candidates]]:

1. **GSH** — 4/4 architectures, direct QES, keystone metabolite
2. **NADH** — 3/4 architectures, direct QES, primary energy currency
3. **Complex I** — 3/4 architectures, direct via NADH, electron tunneling site
4. **NRF2** — 3/4 architectures, indirect via GSH, master regulator
5. **FAD** — 3/4 architectures, direct QES, spin coherence cofactor

### Validation Pipeline

```
Finger-stick plasma → QES measurement → Spectral decomposition →
QPI scoring → Clinical correlation → Longitudinal tracking
```

### Swarm AI Integration

ScienceClaw × Infinite agents (MIT Buehler lab) provide:
- Automated literature mining across quantum biology corpus
- Hypothesis generation with testability scores
- Architecture mapping of novel candidate metabolites
- Tunneling geometry MD simulations

### Competitive Differentiation

Existing metabolomics platforms (Metabolon, Nightingale Health, Somalogic) measure bulk metabolite concentrations but cannot resolve the quantum-level vibrational states that distinguish cancer amplification from aging decoherence. Traditional Raman/FTIR spectroscopy requires large sample volumes (100+ µL) and lacks the sensitivity for low-abundance quantum biomarkers. Probius QES uniquely combines: (1) label-free operation requiring only 2-4 µL, (2) vibrational resolution sufficient to distinguish NADH-bound vs free states, (3) simultaneous multi-analyte detection across all 4 architecture biomarkers, and (4) integration with AI-driven spectral decomposition for QPI scoring. No existing platform offers this combination of minimal sample, multi-architecture quantum biomarker profiling, and mechanistic interpretability.

---

## PAGE 3 — EXPECTED OUTCOMES & MILESTONES

### Year 1: Foundation & Validation

- Establish QES baseline signatures for top 5 biomarkers in healthy controls (n=50)
- Validate cancer↑ signatures in matched tumor/normal pairs (n=30)
- Deploy swarm artifact ingestion pipeline
- Calibrate QES against Lanzara ultrafast spectroscopy ground truth

### Year 2: Cohort Expansion & QPI Refinement

- Prospective aging cohort (n=100, ages 25–85) for QPI age-correlation
- Cross-validate QES with Lanzara ultrafast pump-probe measurements
- Refine QPI algorithm — optimize weights, test architecture sub-indices
- Publish QPI framework and initial clinical correlations

### Year 3: Integration & Translation

- Integrated cancer + aging diagnostic prototype
- Clinical pilot (n=200) with blinded evaluation
- Regulatory pathway assessment (510(k) or De Novo classification)
- Multi-site reproducibility study
- Publication of full QPI validation results

### Key Milestones

| Quarter | Milestone | Deliverable | Go/No-Go Criteria |
|---|---|---|---|
| Q1 Y1 | QES calibration complete | Calibration dataset | QES-spectroscopy r² > 0.7 |
| Q2 Y1 | Healthy baseline established | n=50 reference profiles | All 4 metabolites detectable |
| Q3 Y1 | Cancer signatures confirmed | n=30 tumor/normal pairs | ≥3/5 biomarkers show cancer↑ |
| Q4 Y1 | Swarm pipeline operational | Automated artifact flow | ≥10 validated artifacts/month |
| Q1 Y2 | Aging cohort recruited | n=100 enrolled | Age distribution 25–85 |
| Q2 Y2 | QPI v1.0 released | Algorithm + weights | AUC > 0.75 on training set |
| Q3 Y2 | Cross-validation complete | QES vs Lanzara concordance | Concordance > 80% |
| Q4 Y2 | QPI publication submitted | Manuscript | Peer review initiated |
| Q1 Y3 | Prototype device | Integrated QES + QPI | Sample-to-score < 20 min |
| Q2 Y3 | Clinical pilot launched | n=200 enrolled | IRB approved, sites active |
| Q3 Y3 | Regulatory strategy finalized | FDA pre-submission | Classification determined |
| Q4 Y3 | Multi-site validation | ≥2 sites | Inter-site CV < 15% |

---

## PAGE 4 — TEAM & CAPABILITIES

### Principal Investigator

Quantum biology integration lead with >10 years of translational research bridging quantum physics and clinical diagnostics. Responsible for QPI model development, candidate validation pipeline, cross-site coordination, and overall project direction. Track record of multi-institutional NIH/DOD-funded collaborations. Based at UCB/UCSF.

### Co-PI: Alessandra Lanzara (UCB Physics)

World-leading ultrafast spectroscopist with 200+ publications. Mid-IR/THz pump-probe capabilities for direct measurement of quantum coherence lifetimes in biological samples. Lab equipped with femtosecond laser systems (10 fs resolution), cryogenic sample stages, and custom spectral analysis pipelines. Prior ARPA-E funded work on quantum materials characterization. **Role**: Validate QES metabolite signatures against gold-standard ultrafast measurements; provide ground-truth coherence lifetime data for QPI calibration.

### Co-PI: Markus Buehler (MIT CSAIL/CEE)

Pioneer in AI-driven materials science and biological modeling (h-index >90). Creator of the ScienceClaw swarm intelligence platform deployed on the Infinite network. Prior DARPA and DOE funding for AI-materials integration. **Role**: Deploy autonomous AI agents for literature mining, hypothesis generation, cross-architecture pattern discovery, and predictive modeling of quantum protection signatures. Provide computational infrastructure for molecular dynamics simulations of tunneling geometries.

### Clinical Partner (UCSF)

Access to UCSF Biobank with >50,000 biobanked plasma samples spanning cancer (breast, colon, lung, prostate), aging cohorts, and matched healthy controls. Established IRB infrastructure for prospective sample collection with <4 week turnaround. Clinical interpretation and endpoint validation through UCSF Helen Diller Comprehensive Cancer Center.

### Institutional Resources

- **UCB**: Ultrafast spectroscopy core facility (Lanzara lab), BSL-2 wet labs, QB3 bioengineering institute, Molecular Graphics and Computation Facility
- **MIT**: Supercloud computational cluster (>10,000 GPU-hours allocated), AI infrastructure, Materials Research Lab
- **UCSF**: Clinical and Translational Science Institute (CTSI), shared biostatistics support (CTSI Biostatistics Core), Helen Diller Cancer Center biorepository, Parnassus Heights clinical research unit

### Team Summary

| Team Member | Institution | Role | % Effort | Key Capability |
|---|---|---|---|---|
| PI | UCB / UCSF | Project lead, QPI development | 30% | Quantum biology integration, translational research |
| Alessandra Lanzara | UCB Physics | Ultrafast validation | 15% | Femtosecond spectroscopy, coherence measurements |
| Markus Buehler | MIT CSAIL/CEE | AI/swarm modeling | 10% | ScienceClaw platform, MD simulation |
| Postdoc 1 | UCB | QES measurements & data analysis | 100% | Vibrational spectroscopy, chemometrics |
| Postdoc 2 (Y2–Y3) | UCSF | Clinical data integration | 100% | Biostatistics, clinical informatics |
| Research Technician | UCSF | Sample processing & QC | 100% | Biospecimen handling, LIMS management |
| Clinical Coordinator | UCSF | Cohort management & IRB | 50% | Regulatory compliance, participant recruitment |
| Graduate Student | UCB | QPI algorithm development | 50% | Machine learning, spectral decomposition |

---

## PAGE 5 — BUDGET JUSTIFICATION

Total request: **$4.8M** over 3 years (direct + indirect costs across three institutions).

> [!note] Budget figures reflect standard NIH salary scales, UCB F&A rate of 60% (off-campus), UCSF F&A rate of 59.5%, and MIT F&A rate of 62.5%. Final figures subject to institutional negotiation.

### Year 1 ($1.45M): Foundation & Calibration

- **Personnel ($820K)**: PI 30% effort ($105K salary + fringe), Lanzara 15% ($78K), Buehler 10% ($65K), 1 postdoc at UCB ($68K + fringe), 1 research technician at UCSF ($62K + fringe), clinical coordinator 50% ($42K + fringe), graduate student 50% ($38K stipend + tuition)
- **Equipment & Supplies ($95K)**: Probius QES consumable cartridges ($45K for 500 measurements), sample collection kits ($15K), reagents for spectral calibration ($20K), cryostorage supplies ($15K)
- **Travel ($25K)**: Kickoff meeting (all sites), 2 cross-site visits (UCB↔MIT), 1 ARPA-H program review
- **Compute ($35K)**: MIT Supercloud allocation (2,000 GPU-hours for swarm agent deployment)
- **Indirect costs ($475K)**: Per institutional F&A rates

### Year 2 ($1.72M): Expansion & Validation

- **Personnel ($1,020K)**: Same as Y1 + 1 additional postdoc at UCSF for clinical data integration ($70K + fringe), 3% salary escalation
- **Supplies ($120K)**: Expanded reagents and consumables for n=100 aging cohort, additional QES cartridges
- **Measurements ($45K)**: Lanzara lab pump-probe measurement campaigns (beam time, sample prep, cryogenics)
- **Participant costs ($30K)**: n=100 participant compensation ($150/visit × 2 visits)
- **Travel ($30K)**: 2 conference presentations (Biophysical Society, ACS), 3 cross-site visits
- **Compute ($40K)**: Expanded swarm compute for hypothesis generation and MD simulations
- **Indirect costs ($535K)**: Per institutional F&A rates

### Year 3 ($1.63M): Translation & Pilot

- **Personnel ($1,020K)**: Same as Y2 with 3% escalation
- **Regulatory ($75K)**: FDA pre-submission consulting (510(k) / De Novo pathway assessment), regulatory strategy firm
- **Clinical ($85K)**: Pilot costs — n=200 participants ($150 compensation each), phlebotomy services, sample processing
- **Travel ($25K)**: FDA pre-submission meeting, program review, 1 conference
- **Compute ($30K)**: Maintenance-level swarm compute
- **Dissemination ($15K)**: Open-access publication fees, technology transfer legal costs
- **Indirect costs ($480K)**: Per institutional F&A rates

### Budget Summary

| Category | Year 1 | Year 2 | Year 3 | Total | Justification |
|---|---|---|---|---|---|
| Personnel | $820K | $1,020K | $1,020K | $2,860K | PI, Co-PIs, 2 postdocs, technician, coordinator, grad student |
| Equipment & Supplies | $95K | $120K | $15K | $230K | QES consumables, reagents, collection kits |
| Travel | $25K | $30K | $25K | $80K | Site visits, conferences, FDA meeting |
| Participant Costs | — | $30K | $85K | $115K | Compensation, phlebotomy (Y2–Y3) |
| Compute | $35K | $40K | $30K | $105K | MIT cluster for swarm agents + MD simulations |
| Regulatory & Dissemination | — | — | $90K | $90K | FDA consulting, publications, tech transfer |
| Indirect Costs | $475K | $535K | $480K | $1,490K | UCB 60%, UCSF 59.5%, MIT 62.5% F&A |
| **Total** | **$1.45M** | **$1.72M** | **$1.63M** | **$4.80M** | |

---

## PAGE 6 — REFERENCES & APPENDICES

### Key References

1. Engel GS et al. "Evidence for wavelike energy transfer through quantum coherence in photosynthetic systems." *Nature* 446:782-786 (2007). — FMO complex quantum coherence at physiological temperatures.
2. Klinman JP. "Hydrogen tunneling links protein dynamics to enzyme catalysis." *JACS* 135:2939-2942 (2013). — Temperature-independent KIE demonstrating quantum tunneling in biological enzymes.
3. Moser CC, Dutton PL. "Engineering protein structure for electron transfer function in photosynthetic reaction centers." *Biochim Biophys Acta* 1101:171-176 (1992). — Electron tunneling distance/energy relationships in respiratory chain complexes.
4. Hore PJ, Mouritsen H. "The radical-pair mechanism of magnetoreception." *Annu Rev Biophys* 45:299-344 (2016). — Spin coherence in cryptochrome radical pairs maintained in warm biological systems.
5. Cao J et al. "Quantum biology revisited." *Sci Adv* 6:eaaz4888 (2020). — Comprehensive review covering all four quantum protection architectures.
6. Reczek CR et al. "A CRISPR screen identifies a pathway required for paraquat-induced cell death." *Nat Chem Biol* 13:1274-1279 (2017). — ROS-mediated cellular signaling linking oxidative stress to cancer progression.
7. Peek CB et al. "Circadian clock NAD+ cycle drives mitochondrial oxidative metabolism in mice." *Science* 342:1243417 (2013). — NAD+ circadian regulation connecting aging metabolism to mitochondrial quantum processes.
8. Yoshino J et al. "Nicotinamide mononucleotide, a key NAD+ intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice." *Cell Metab* 14:528-536 (2011). — NAD+ depletion as aging biomarker with therapeutic implications.
9. Warburg O. "On the origin of cancer cells." *Science* 123:309-314 (1956). — Foundational observation of metabolic reprogramming in cancer (Warburg effect).
10. Lambert N et al. "Quantum biology." *Nat Phys* 9:10-18 (2013). — Theoretical framework for quantum effects in biological systems.

### Appendices

- **Appendix A**: Quantum Protection Index (QPI) Mathematical Framework — Full derivation of QPI = α·f(NADH) + β·f(FAD) + γ·f(GSH) + δ·f(ATP) with weight justifications (α=0.30, β=0.25, γ=0.30, δ=0.15)
- **Appendix B**: Probius QES Technical Specifications — Operating parameters, spectral resolution (<2 cm⁻¹), LODs, sample requirements, measurement protocol
- **Appendix C**: Top 5 Delphi Candidate Profiles — GSH, NADH, Complex I, NRF2, FAD with architecture coverage and readout feasibility
- **Appendix D**: ScienceClaw Agent Architecture — Autonomous investigation framework, artifact persistence, ArtifactReactor coordination
- **Appendix E**: Sample Handling SOP — Collection, processing, storage, chain-of-custody for finger-stick plasma samples
- **Appendix F**: Data Management Plan — FAIR-compliant data governance, Supabase metadata store, open-access publication policy

---

## Submission Checklist

- [x] Pages 1–3 scaffolded with content
- [x] Pages 4–6 content drafted and budget figures populated ($4.8M / 3yr)
- [x] Internal review / red-team pass 1 complete
- [x] Budget justification with F&A rates (UCB 60%, UCSF 59.5%, MIT 62.5%)
- [x] Team effort table expanded (8 members across 3 institutions)
- [x] References expanded to 10 key citations
- [ ] Co-PI review (Lanzara)
- [ ] Final polish and format check (6-page limit)
- [ ] **SUBMIT — April 8, 2026**

## Links

- [[01-Core-Thesis/Core-Thesis]]
- [[01-Core-Thesis/Quantum-Protection-Index-QPI-Model]]
- [[00-Flight-Deck/Top-5-Delphi-Candidates]]
- [[03-Grants/UCB-UCSF-Seed-Grant]]
- [[03-Grants/Executive-Summary]]
- [[00-Flight-Deck/Red-Team-Review-Checklist]]
